Publications by authors named "Michael J Ackerman"

Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, potentially life-threatening genetic heart disease. Nonselective beta-blockers (BBs) are highly effective in reducing CPVT-triggered arrhythmic events. However, some patients suffer from unacceptable BB side effects and might require strategies without a BB.

View Article and Find Full Text PDF

Background: Congenital long-QT syndrome (LQTS) is characterized by delayed ventricular repolarization, predisposing to potentially lethal ventricular arrhythmias. The variability in disease severity among patients remains largely unexplored, underscoring the limitations of current risk stratification methods.

Objective: We aimed to evaluate the potential utility of exercise stress test (EST) electrocardiographic markers in identifying high-risk LQTS patients.

View Article and Find Full Text PDF

Unexplained sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in the young remains a critical issue for clinicians, researchers, patients and their family members. In this review, we explore the current status of SCA and SCD evaluation in the young, including recent monogenic and polygenic disease discoveries, advancements in cardiac imaging and our growing understanding of the role of the Purkinje system in triggering life threatening and even fatal ventricular arrhythmias. Yet, despite these advancements, over a third of SCA and SCD among individuals with seemingly structurally normal hearts remain unexplained.

View Article and Find Full Text PDF
Article Synopsis
  • Long QT syndrome (LQTS) is a heart condition associated with prolonged QT intervals, which can lead to serious events like arrhythmias and sudden cardiac arrest. The study aims to explore if patients with untreated LQTS experience chronotropic insufficiency (CI), a condition where the heart cannot sufficiently increase its rate in response to exercise.
  • A retrospective analysis was conducted on 463 patients with different LQTS genotypes (LQT1, LQT2, LQT3), focusing on those who were not on beta blockers; about 51% of these patients exhibited CI, with LQT1 patients showing the highest prevalence.
  • The findings suggest that while patients with LQTS, especially LQT1, have
View Article and Find Full Text PDF

Objective: To determine the prevalence, penetrance, and disease expression of cardiomyopathy-related genetic variants in an unselected, richly phenotyped Mayo Clinic population in the setting of preemptive sequencing, with return of incidental findings following the American College of Medical Genetics and Genomics recommendations.

Patients And Methods: We analyzed a quaternary medical center-based biobank cohort (n=983) for reportable variants in 15 cardiomyopathy genes. Prioritization of genetic variants was performed using an internally developed pipeline to identify potentially reportable variants.

View Article and Find Full Text PDF
Article Synopsis
  • Guideline-directed therapy for LQTS has changed, with varying ICD recommendations depending on cardiac societies.
  • A study analyzed 2861 patients with LQT types to see who met the 2022 guidelines for ICDs and compared outcomes for those with and without an ICD.
  • Results showed that while many patients met recommendations for ICDs, more than half did not receive one, and those without an ICD had significantly fewer cardiac events than those with one.
View Article and Find Full Text PDF
Article Synopsis
  • Historically, people with Hypertrophic Cardiomyopathy (HCM) were discouraged from playing intense competitive sports due to fears of sudden death.
  • Recent studies indicate that individuals with HCM engaging in vigorous sports may not face a higher risk of heart arrhythmias compared to less active individuals.
  • Current guidelines are adapting to recommend personalized assessments and shared decision-making for HCM athletes looking to return to their sports.
View Article and Find Full Text PDF

Background: Long QT syndrome is a lethal arrhythmia syndrome, frequently caused by rare loss-of-function variants in the potassium channel encoded by . Variant classification is difficult, often because of lack of functional data. Moreover, variant-based risk stratification is also complicated by heterogenous clinical data and incomplete penetrance.

View Article and Find Full Text PDF
Article Synopsis
  • * The study analyzed tissues from 97 patients with symptomatic obstructive HCM through RNA-sequencing and mass spectrometry, revealing significant differences in gene and protein expressions between males and females, though overall profiles were similar.
  • * Findings indicate that HCM females show greater downregulation of hypertrophy pathways and have more differentially expressed proteins compared to control females than what is observed in males, highlighting biologically relevant sex-specific differences in disease mechanisms.
View Article and Find Full Text PDF

Introduction: We have previously reported that genetically positive patients have a more profound early decrease in provocable left ventricular outflow tract gradient compared to genetically negative patients utilizing mavacamten in the first 12 weeks of therapy.

Methods And Results: In this current analysis, we found that genetically positive patients have less favorable remodeling as measured by left ventricular wall thickness regression when evaluated long-term as compared to genetically negative patients, despite an overall better early response to mavacamten. The majority of genetically positive patients were maintained on only 2.

View Article and Find Full Text PDF

Background: Genetic testing for cardiac channelopathies is the standard of care. However, many rare genetic variants remain classified as variants of uncertain significance (VUS) due to lack of epidemiological and functional data. Whether deep protein language models may aid in VUS resolution remains unknown.

View Article and Find Full Text PDF

Background And Aims: Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy.

View Article and Find Full Text PDF

Aims: Recently, deep learning artificial intelligence (AI) models have been trained to detect cardiovascular conditions, including hypertrophic cardiomyopathy (HCM), from the 12-lead electrocardiogram (ECG). In this external validation study, we sought to assess the performance of an AI-ECG algorithm for detecting HCM in diverse international cohorts.

Methods And Results: A convolutional neural network-based AI-ECG algorithm was developed previously in a single-centre North American HCM cohort (Mayo Clinic).

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers developed a new gene therapy called CALM-SupRep, designed to suppress and replace malfunctioning genes associated with this syndrome using custom-made shRNAs.
  • * The therapy successfully reduced elongated action potential durations in patient-derived heart cells, demonstrating potential as a viable treatment option for this condition.
View Article and Find Full Text PDF
Article Synopsis
  • * The 2023 ACC/AHA guidelines recommend genetic testing for AF patients aged 45 or younger to enhance personalized care and prognosis by identifying specific genetic defects.
  • * Challenges in genetic testing for AF include interpreting uncertain results, financial and insurance barriers, and the need for improved training and standardization in testing procedures.
View Article and Find Full Text PDF

Background: Despite major advances in the clinical management of long QT syndrome, some patients are not fully protected by beta-blocker therapy. Mexiletine is a well-known sodium channel blocker, with proven efficacy in patients with sodium channel-mediated long QT syndrome type 3. Our aim was to evaluate the efficacy of mexiletine in long QT syndrome type 2 (LQT2) using cardiomyocytes derived from patient-specific human induced pluripotent stem cells, a transgenic LQT2 rabbit model, and patients with LQT2.

View Article and Find Full Text PDF
Article Synopsis
  • - The text discusses Calcium Release Deficiency Syndrome (CRDS), a serious genetic heart condition that can cause sudden cardiac arrest without clear reasons and is not detectable through standard tests.
  • - The study aimed to analyze electrocardiogram (ECG) responses after brief periods of fast heart rates followed by pauses in order to develop a diagnostic test for CRDS.
  • - Findings showed that patients with CRDS had a significantly greater change in T-wave amplitude on their ECG after a pause compared to control groups, indicating a potential diagnostic marker for this syndrome.
View Article and Find Full Text PDF

Background: Energy drinks potentially can trigger life-threatening cardiac arrhythmias. It has been postulated that the highly stimulating and unregulated ingredients alter heart rate, blood pressure, cardiac contractility, and cardiac repolarization in a potentially proarrhythmic manner.

Objective: The purpose of this study was to describe our experience regarding sudden cardiac arrest (SCA) occurring in proximity to energy drink consumption in patients with underlying genetic heart diseases.

View Article and Find Full Text PDF